Osteosarcoma

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
4 Unique sponsors
4 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 2 substances
Kinase inhibitor 1 substance
Unknown / small molecule 1 substance
Phase II: 2 Phase I/II: 1 Phase I: 2

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase II

2 trials
  • Ipsen Innovation Commercial
    CABOZANTINIB
    2023-506229-12-00 11 countries 2024 n=86
    Ended
  • Instytut Matki I Dziecka Academic
    IMP not specified
    2026-525223-24-00 1 country n=40
    Pending

Phase I/II

1 trial
  • Glaxosmithkline Research & Development Limited Commercial
    COBOLIMAB; DOSTARLIMAB
    2024-511350-41-00 6 countries 2025 n=46
    Ended

Phase I

2 trials
  • Universitaet Muenster Academic
    GD2IL18CART
    2022-501725-21-00 1 country 2024 n=48
    Recruiting
  • Universitaet Muenster Academic
    GD2IL18CART
    2025-521497-34-00 1 country 2025 n=20
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Universitaet Muenster Academic 2 Phase I 2
Ipsen Innovation Commercial 1 Phase II 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase I/II 0
Instytut Matki I Dziecka Academic 1 Phase II 0
New trials by year
2024
2
2025
2
← All indication landscapes